V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160017080 | 160013541 | 0 | 82.3 | Palliative (P) | 2021-05-13 | 2021-05-17 | CYCLOPHOSPHAMIDE + VINORELBINE | 02 | N | LENVATINIB | 101292714 |
| 160017081 | 160013542 | 0.97 | 16.4 | Curative (C) | 2017-02-06 | 2017-04-02 | IVA | 02 | N | LENALIDOMIDE | 100257167 |
| 160017082 | 160013543 | 0.98 | 67.9 | null | 2017-02-08 | 2017-02-22 | Gemcitabine day 1&8 | 02 | null | VENETOCLAX | 100720300 |
| 160017084 | 160013544 | 1.71 | 16.4 | Curative (C) | null | 2016-09-30 | IVA | N | Y | LIPOSOMAL DAUNORUBICIN | 100699224 |
| 160017091 | 160013545 | null | 75.9 | Curative (C) | 2017-11-19 | 2018-09-16 | CYCLOPHOSPHAMIDE + VINORELBINE | 02 | N | IPILIMUMAB + NIVOLUMAB | 101284569 |
| 160017098 | 160013546 | 1.6 | 55.2 | null | 2018-04-26 | 2018-04-27 | NB HRNBL-1 TVD | 02 | null | RUCAPARIB | 100806426 |
| 160017102 | 160013547 | 1.64 | 72.3 | Palliative (P) | 2017-08-27 | 2017-09-21 | Etoposide oral | 01 | N | ETOP 13-18 BEAT-MESO TRIAL | 100353353 |
| 160017106 | 160013548 | 1.74 | 70.3 | null | 2018-07-17 | 2018-12-31 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | null | VENETOCLAX | 100451101 |
| 160017109 | 160013549 | 1.79 | 17.8 | Curative (C) | 2017-03-24 | 2017-05-19 | Pemetrexed | 01 | N | NB RELAPSED CYCLOPHOSPHAMIDE AND TOPOTECAN | 101100354 |
| 160017112 | 160013550 | 1.74 | 84.6 | Palliative (P) | 2017-04-06 | 2019-05-22 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | CARBOPLATIN + ETOPOSIDE | 101236376 |
| 160017114 | 160013551 | 1.64 | 55.2 | Curative (C) | 2017-01-03 | 2017-01-23 | EW EuroEwing 2012 Arm B VDC/IE | 01 | N | DOXORUBICIN + IFOSFAMIDE | 101694963 |
| 160017115 | 160013552 | 1.64 | 84.6 | null | 2019-09-21 | 2020-01-12 | VIDE | 02 | null | DACARBAZINE | 101833931 |
| 160017118 | 160013553 | 1.87 | 74 | Adjuvant (A) | 2016-05-20 | 2016-05-20 | Rucaparib | 02 | N | ENZALUTAMIDE | 100573082 |
| 160017119 | 160013554 | 1.64 | 55.1 | Curative (C) | 2020-04-18 | 2020-04-18 | Doxorubicin + Ifosfamide | 02 | N | PEMBROLIZUMAB | 100674859 |
| 160017127 | 160013555 | 1.68 | 79.2 | Neo-adjuvant (N) | 2019-09-20 | 2019-10-08 | Doxorubicin + Ifosfamide | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 VA | 101584547 |
| 160017128 | 160013556 | 1.66 | 69.6 | Curative (C) | 2017-01-08 | 2017-01-14 | Dacarbazine | N | null | EW EUROEWING 2012 ARM B IE | 100315424 |
| 160017129 | 160013557 | 1.68 | 68.7 | Curative (C) | 2017-06-21 | 2017-07-01 | STS Rhabdomyosarcoma RMS 2005 IVA | null | null | RUCAPARIB | 100423018 |
| 160017140 | 160013558 | 1.42 | 71.35 | null | 2020-06-23 | 2020-06-28 | Trial Unspecified | 02 | null | STS RHABDO RMS 2005 VIN CYCLO | 100022048 |
| 160017142 | 160013559 | 1.8 | 85.7 | null | 2021-07-02 | 2021-07-02 | Gemcitabine weekly | 02 | null | CYCLOPHOSPHAMIDE + TOPOTECAN | 100453677 |
| 160017143 | 160013560 | 1.86 | 67.5 | null | 2018-01-20 | 2018-02-23 | IPILIMUMAB + NIVOLUMAB | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 VA | 101237274 |
| 160017144 | 160013561 | 0 | 47.7 | null | 2017-07-09 | 2017-07-09 | EW EuroEwing 2012 Arm A/B Zol Acid | 02 | null | CISPLATIN + ETOPOSIDE | 101293282 |
| 160017151 | 160013563 | 1.86 | 72 | Palliative (P) | 2016-09-08 | 2016-09-28 | Dacarbazine | Y | N | STS RHABDO RMS 2005 VIN CYCLO | 101212727 |
| 160017153 | 160013564 | 0 | 91.1 | Palliative (P) | 2017-11-14 | 2017-12-04 | Ifosfamide | 02 | N | NB RELAPSED CYCLOPHOSPHAMIDE AND TOPOTECAN | 101777661 |
| 160017158 | 160013565 | null | 99.1 | Palliative (P) | 2017-03-18 | 2018-03-25 | EW Rel rEECur Irinotecan/Temozolomide | 02 | N | IPILIMUMAB + NIVOLUMAB | 101600360 |
| 160017159 | 160013566 | null | null | Neo-adjuvant (N) | 2019-08-22 | 2019-09-12 | ABEMACICLIB + FULVESTRANT | 02 | N | IPILIMUMAB + NIVOLUMAB | 101794810 |
| 160017162 | 160013567 | null | 93.9 | null | 2019-04-09 | 2019-09-02 | ETOP 13-18 BEAT-meso Trial | 02 | null | CYCLOPHOSPHAMIDE | 100936393 |
| 160017164 | 160013568 | 1.64 | 70 | null | null | 2019-08-26 | PEMBROLIZUMAB | 02 | null | ETOP 13-18 BEAT-MESO TRIAL | 100139910 |
| 160017165 | 160013569 | 1.58 | 82.2 | Neo-adjuvant (N) | 2018-04-04 | 2018-04-28 | STS Rhabdo RMS 2005 Vin Cyclo | N | null | NB HRNBL-1 ISOTRETINOIN | 100739403 |
| 160017166 | 160013570 | 0 | 60.8 | Curative (C) | 2019-03-12 | 2019-03-28 | Gemcitabine day 1&8 | 02 | N | OCTOPUS TRIAL | 101531354 |
| 160017170 | 160013571 | 1.5 | 125.3 | Curative (C) | 2017-02-21 | 2017-03-28 | Cyclophosphamide + Vincristine | N | N | NB RELAPSED CYCLOPHOSPHAMIDE AND TOPOTECAN | 100747430 |
| 160017172 | 160013572 | null | null | null | 2017-01-03 | 2017-05-01 | IVA | 02 | null | STS RHABDO RMS 2005 VIN CYCLO | 101312607 |
| 160017174 | 160013573 | 1.82 | 80.4 | Palliative (P) | null | 2019-02-13 | IPM | 02 | null | CONFIRM TRIAL | 100074163 |
| 160017176 | 160013574 | null | 76.3 | Palliative (P) | 2019-03-11 | 2019-03-20 | null | N | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 100445707 |
| 160017179 | 160013575 | 1.95 | 97.9 | Palliative (P) | 2013-09-02 | 2013-09-10 | Doxorubicin + Ifosfamide | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 100043144 |
| 160017180 | 160013576 | 1.54 | 104 | Neo-adjuvant (N) | 2018-05-08 | 2019-10-20 | NB Rel CCLG guidelines Cyclo-Topotecan | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101450540 |
| 160017182 | 160013577 | 1.63 | 92.9 | null | 2021-06-15 | 2021-06-28 | ATOMIC-MESO TRIAL | null | null | GEMCITABINE | 100369669 |
| 160017185 | 160013579 | 0 | 77.9 | null | 2017-10-18 | 2017-11-01 | IPM | 02 | null | OLARATUMAB | 100119827 |
| 160017186 | 160013580 | 0 | 92.7 | Neo-adjuvant (N) | 2017-03-05 | 2018-12-07 | ETOPOSIDE + IFOSFAMIDE | 01 | null | GEMCITABINE | 101204364 |
| 160017187 | 160013581 | 1.5 | 52.3 | Palliative (P) | 2019-06-12 | 2019-06-24 | CYCLOPHOSPHAMIDE + VINORELBINE | 2 | N | TOPOTECAN | 100982620 |
| 160017190 | 160013582 | 1.61 | 67.3 | Curative (C) | 2019-04-14 | 2019-04-14 | CONFIRM TRIAL | 02 | N | FLAIR TRIAL | 101300246 |
| 160017194 | 160013583 | 1.79 | 14.5 | Palliative (P) | null | 2019-03-03 | Gemcitabine 1000mg/m2 D1 8 15 | 02 | null | IFOSFAMIDE | 101188298 |
| 160017196 | 160013584 | 0 | 19.2 | Neo-adjuvant (N) | 2018-01-28 | 2018-02-12 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | IVADO | 100729238 |
| 160017199 | 160013585 | 1.57 | 18 | Curative (C) | 2018-06-14 | 2018-06-14 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | null | EW EUROEWING 2012 ARM B VC | 100719924 |
| 160017200 | 160013586 | 0 | 76.5 | Curative (C) | 2019-06-07 | 2019-06-20 | Cyclophosphamide oral | 02 | N | GEMCITABINE | 101515987 |
| 160017207 | 160013587 | null | 64 | null | 2017-10-18 | 2017-10-18 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | null | STS NON-RHABDO EPSSG 2005 IFOS | 101150301 |
| 160017208 | 160013588 | null | 105 | Palliative (P) | 2017-11-10 | 2017-11-17 | STS Non-Rhabdo EpSSG 2005 IVA | 02 | N | RITUXIMAB | 100949959 |
| 160017212 | 160013589 | null | 51.1 | Curative (C) | 2018-01-02 | 2018-01-04 | GEMCITABINE | 01 | N | OLAPARIB | 101707123 |
| 160017216 | 160013590 | 1.69 | 72.5 | null | 2017-06-30 | 2017-07-01 | null | 02 | null | ETOPOSIDE + IFOSFAMIDE | 101196585 |
| 160017217 | 160013591 | 1.89 | 19.6 | Curative (C) | null | null | DARATUMUMAB | 02 | N | IFOSFAMIDE | 100378296 |
| 160017219 | 160013592 | 1.82 | 55.6 | Palliative (P) | 2016-06-02 | 2016-09-26 | EW Rel rEECur Irinotecan/Temozolomide | 02 | N | EW EUROEWING 2012 ARM A VAI | 101529211 |